Mavupharma, a Kirkland, Wash.-based a drug discovery and development company, secured $20m in Series A financing.
The round was led by Frazier Healthcare Partners with participation from Alpine BioVentures. As part of the financing, Bob Baltera, chief executive officer of Cirius Therapeutics, will serve as executive chairman of the board.
The company intends to use the funds to advance its lead drug candidates into the clinic.
Led by Michael Gallatin, Ph.D., president, and Greg Dietsch, Ph.D., Mavupharma develops orally bioavailable, non-nucleotide modulators of the STING (stimulator of interferon genes) pathway to treat cancer and infectious diseases.